HLA class II and response to interferon-beta in multiple sclerosis

被引：30

作者：

Fernández, O

Fernández, V

Mayorga, C

Guerrero, M

León, A

Tamayo, JA

Alonso, A

Romero, F

Leyva, L

Alonso, A

Luque, G

de Ramón, E

机构：

[1] Hosp Reg Univ Carlos Haya, Inst Clin Neurosci, Malaga 29010, Spain

[2] Hosp Reg Univ Carlos Haya, Res Unit, Malaga 29010, Spain

[3] Hosp Reg Univ Carlos Haya, Dept Immunol, Malaga 29010, Spain

[4] Hosp Clin Univ San Cecilio, Dept Neurol, Granada, Spain

来源：

ACTA NEUROLOGICA SCANDINAVICA | 2005年 / 112卷 / 06期

关键词：

multiple sclerosis; HLA class II; interferon beta; treatment; response;

D O I：

10.1111/j.1600-0404.2005.00415.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objective -To study the relationship between human leucocyte antigen (HLA) genotype and clinical response to interferon-beta (IFN-beta). Methods -We analysed the HLA class II genotypes of 96 multiple sclerosis (MS) patients treated with IFN-beta. The patients were classified as responders or non-responders according to clinical criteria: one or more relapses or a sustained increase after 1 year treatment compared with the year prior to IFN-beta therapy of >= 0.5 points on the Expanded Disability Status Scale (EDSS). Results -There were 66 (69%) responders and 30 (31%) non-responders. Baseline clinical characteristics were similar. We found no association between HLA class II alleles and clinical response to IFN-beta. Conclusions -HLA genotype does not appear to influence the clinical response to IFN-beta in MS patients.

引用

收藏

页码：391 / 394

页数：4

相关论文

共 18 条

[1] Identifying and treating patients with suboptimal responses [J].

Cohen, BA ;

Khan, O ;

Jeffery, DR ;

Bashir, K ;

Rizvi, SA ;

Fox, EJ ;

Agius, M ;

Bashir, R ;

Collins, TE ;

Herndon, R ;

Kinkel, P ;

Mikol, DD ;

Picone, MA ;

Rivera, V ;

Tornatore, C ;

Zwibel, H .

NEUROLOGY, 2004, 63 (12) :S33-S40

[2] Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders [J].

Cohen, JA ;

Carter, JL ;

Kinkel, RP ;

Schwid, SR .

JOURNAL OF NEUROIMMUNOLOGY, 1999, 98 (01) :29-36

[3] Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients? [J].

Durelli, L ;

Oggero, A ;

Verdun, E ;

Isoardo, G ;

Ricci, A ;

Barbero, P ;

Bergamasco, B .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2000, 178 (01) :37-41

[4] DQB1*0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain [J].

Fernández, O ;

Fernández, V ;

Alonso, A ;

Caballero, A ;

Luque, G ;

Bravo, M ;

León, A ;

Mayorga, C ;

Leyva, L ;

de Ramón, E .

JOURNAL OF NEUROLOGY, 2004, 251 (04) :440-444

[5]

FERNANDEZ O, 2003, ESCLEROSIS MULTIPLE, P36

[6] HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis [J].

Fusco, C ;

Andreone, V ;

Cappola, G ;

Luongo, V ;

Guerini, F ;

Pace, E ;

Florio, C ;

Pirozzi, G ;

Lanzillo, R ;

Ferrante, P ;

Vivo, P ;

Mini, M ;

Macrì, M ;

Orefice, G ;

Lombardi, ML .

NEUROLOGY, 2001, 57 (11) :1976-1979

[7] Disease modifying therapies in multiple sclerosis - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [J].

Goodin, DS ;

Frohman, EM ;

Garmany, GP ;

Halper, J ;

Likosky, WH ;

Lublin, FD ;

Silberberg, DH ;

Stuart, WH ;

van den Noort, S .

NEUROLOGY, 2002, 58 (02) :169-178

[8] HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis [J].

Hensiek, AE ;

Sawcer, SJ ;

Feakes, R ;

Deans, J ;

Mander, A ;

Akesson, E ;

Roxburgh, R ;

Coraddu, F ;

Smith, S ;

Compston, DAS .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 72 (02) :184-187

[9] HUMAN-LEUKOCYTE ANTIGEN STUDIES IN MULTIPLE-SCLEROSIS [J].

HILLERT, J .

ANNALS OF NEUROLOGY, 1994, 36 :S15-S17

[10] The genetics of multiple sclerosis. A review [J].

Kalman, B ;

Lublin, FD .

BIOMEDICINE & PHARMACOTHERAPY, 1999, 53 (08) :358-370